<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Invasive <z:e sem="disease" ids="C0026946" disease_type="Disease or Syndrome" abbrv="">fungal infections</z:e> (IFI) are an important cause of morbidity, increased hospitalization and healthcare costs in <z:e sem="disease" ids="C0010340" disease_type="Disease or Syndrome" abbrv="">critically ill</z:e> or immunocompromised children </plain></SENT>
<SENT sid="1" pm="."><plain>The mortality is comprised between 5 and 20% </plain></SENT>
<SENT sid="2" pm="."><plain>In the last 2 decades, the epidemiology of <z:e sem="disease" ids="C0877445" disease_type="Disease or Syndrome" abbrv="">candidemia</z:e> has changed with an increase of episodes caused by non-Candida albicans species </plain></SENT>
<SENT sid="3" pm="."><plain>Central venous catheter, diagnosis of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e>, and receipt of either <z:chebi fb="0" ids="28001">vancomycin</z:chebi> or antimicrobials with activity against anaerobic organisms for &gt;3 days have been associated with the development of <z:e sem="disease" ids="C0877445" disease_type="Disease or Syndrome" abbrv="">candidemia</z:e> in the pediatric intensive care unit (PICU) </plain></SENT>
<SENT sid="4" pm="."><plain>Additional risk factors found in hematological patients were the diagnosis of <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo>, performing an unrelated bone marrow or cord blood transplant, the occurrence of a <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft versus host disease</z:e> and the use of steroids </plain></SENT>
<SENT sid="5" pm="."><plain>Early antifungal treatment is recommended to reduce mortality </plain></SENT>
<SENT sid="6" pm="."><plain>In neutropenic patients, <z:chebi fb="0" ids="2682">liposomal amphotericin B</z:chebi>, an echinocandin (caspofungin, micafungin), and <z:chebi fb="0" ids="10023">voriconazole</z:chebi> are considered the best option especially for C. glabrata and C. krusei </plain></SENT>
<SENT sid="7" pm="."><plain><z:chebi fb="2" ids="46081">Fluconazole</z:chebi> remains a valid option for <z:e sem="disease" ids="C0276680" disease_type="Disease or Syndrome" abbrv="">infection by Candida albicans</z:e> in patients not exposed to <z:chebi fb="2" ids="46081">fluconazole</z:chebi> prophylaxis </plain></SENT>
<SENT sid="8" pm="."><plain>Amphotericn B deoxy-<z:chebi fb="0" ids="29747">cholate</z:chebi> is generally not recommended because of its nephrotoxicity </plain></SENT>
</text></document>